Literature DB >> 32431947

Synthesis, crystal structure and Hirshfeld surface analysis of N-(4-chloro-phen-yl)-5-cyclo-propyl-1-(4-meth-oxy-phen-yl)-1H-1,2,3-triazole-4-carboxamide.

Nazariy Pokhodylo1, Yurii Slyvka2, Volodymyr Pavlyuk2.   

Abstract

The title compound, C19H17ClN4O2, was obtained via a two-step synthesis involving the enol-mediated click Dimroth reaction of 4-azido-anisole with methyl 3-cyclo-propyl-3-oxo-propano-ate leading to the 5-cyclo-propyl-1-(4-meth-oxy-phen-yl)-1H-1,2,3-triazole-4-carb-oxy-lic acid and subsequent acid amidation with 4-chloro-aniline by 1,1'-carbonyl-diimidazole (CDI). It crystallizes in space group P21/n, with one mol-ecule in the asymmetric unit. In the extended structure, two mol-ecules arranged in a near coplanar fashion relative to the triazole ring planes are inter-connected by N-H⋯N and C-H⋯N hydrogen bonds into a homodimer. The formation of dimers is a consequence of the above inter-action and the edge-to-face stacking of aromatic rings, which are turned by 58.0 (3)° relative to each other. The dimers are linked by C-H⋯O inter-actions into ribbons. DFT calculations demonstrate that the frontier mol-ecular orbitals are well separated in energy and the HOMO is largely localized on the 4-chloro-phenyl amide motif while the LUMO is associated with aryl-triazole grouping. A Hirshfeld surface analysis was performed to further analyse the inter-molecular inter-actions. © Pokhodylo et al. 2020.

Entities:  

Keywords:  1,2,3-triazole; DFT calculation; Hirshfeld surface analysis; crystal structure

Year:  2020        PMID: 32431947      PMCID: PMC7199270          DOI: 10.1107/S2056989020005848

Source DB:  PubMed          Journal:  Acta Crystallogr E Crystallogr Commun


Chemical context

The number of compounds containing a 1,2,3-triazolyl-4-carboxamide motif that are known to exhibit biological activity is increasing rapidly. At present, there are two approved drugs and a number of compounds are undergoing preclinical studies. For instance, rufinamide is a well-known drug among those currently marketed, which is used to treat Lennox–Gastaut syndrome (childhood-onset epilepsy) (Wheless & Vazquez, 2010 ▸). Carb­oxy­amido­triazole is a calcium channel blocker (Figg et al., 1995 ▸) and is currently being actively investigated as an anti­cancer drug in vitro (Bonnefond et al., 2018 ▸). As an example of preclinical anti­cancer studies, the cytotoxic activity at nanomolar levels of asymmetric 1-R-N-[(1-R-1H-1,2,3-triazol-4-yl)meth­yl]-1H-1,2,3-triazole-4-carb­oxamides in B16 melanoma cells have been estimated (Elamari et al., 2013 ▸). In our previous studies on the anti­cancer screening of various 1,2,3-triazoles, compounds based on 1,2,3-triazolyl-4-carboxamide scaffolds possessed the highest anti­proliferative activity (Shyyka et al., 2019 ▸; Pokhodylo et al., 2013 ▸, 2014 ▸). Furthermore, a series of 6,7-disubstituted-4-(2-fluoro­phen­oxy)quinoline derivatives possessing the 1,2,3-triazole-4-carboxamide moiety have been evaluated against c-Met kinase and five typical cancer cell lines (A549, H460, HT-29, MKN-45 and U87MG) and exhibited moderate to excellent anti­proliferative activity (Zhou et al., 2014 ▸). A library of 1-benzyl-N-(2-(phenyl­amino)­pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamides was screened for their anti­proliferative activity and showed promising cytotoxicity against lung cancer cell line A549 (Prasad et al., 2019 ▸). In addition to the anti­tumor studies, 1H-1,2,3-triazole-4-carboxamides exhibit other biological activities such as fungicidal (Wang et al., 2014 ▸), anti­viral (Krajczyk et al., 2014 ▸) and anti­microbial (Jadhav et al., 2017 ▸) activities and were found to be inhibitors of the Wnt/β-catenin signalling pathway (Obianom et al., 2019 ▸). It should be noted that the diversity of such compounds can be obtained by amidation of 1H-1,2,3-triazole-4-carb­oxy­lic acids prepared by convenient Dimroth synthesis and further modifications (Pokhodylo et al., 2009 ▸, 2017 ▸, 2018 ▸; Pokhodylo, Matiychuk et al., 2010 ▸; Pokhodylo, Savka et al., 2010 ▸; Pokhodylo & Obushak, 2019 ▸). Given the considerable inter­est in such scaffolds for drug discovery, a detailed study of their structural features is relevant and the crystal structure of the title compound, C19H17ClN4O2, is described herein.

Structural commentary

The title compound crystallizes in the monoclinic centrosymmetric space group P21/n, with one mol­ecule in the asymmetric unit. As shown in Fig. 1 ▸, the 4-meth­oxy­phenyl and 1,2,3-triazole rings are turned relative to each other by 87.77 (7)° because of a significant steric hindrance of the cyclo­propyl ring relative to the 4-meth­oxy­phenyl substituent [the N1—C9—C11—C13 and N1—C9—C11—C12 torsion angles are 41.2 (4) and −31.6 (4)°, respectively]. The above angle between the planes is comparable with that for the bulky 5-(2-phenyl­hydrazineyl­idene)methyl analogue [73.3 (2)°; Pokhodylo et al., 2018 ▸] but is considerably larger than in the structure of 5-cyclo­propyl-1-(3-meth­oxy­phen­yl)-1H-1,2,3-triazole-4-carb­oxy­lic acid [39.1 (2)°] in which the cyclo­propyl ring is oriented to the triazole ring (Pokhodylo et al., 2017 ▸) or in 5-methyl-1-(4-nitro­phen­yl)-1H-1,2,3-triazol-4-yl­phospho­n­ate [45.36 (6)°; Pokhodylo et al., 2020 ▸]. In selected 5-free triazoles, 1-(3-bromo- or 4-fluoro­phen­yl)-1H-1,2,3-triazol-4-yl)methyl methyl­phospho­nates, this angle is 22.9 (3) and 15.7 (2)°, respectively (Pokhodylo, Shyyka et al., 2019 ▸). Within the cyclo­propyl ring in the title compound, the three CC bond lengths differ by an insignificant amount [C11—C12 = 1.491 (3), C11—C13 = 1.475 (3), C12—C13 = 1.457 (3) Å]. The amide group is turned slightly by 7.5 (3)° relative to the triazole ring while the proton of the amide group is involved in an intra­molecular hydrogen bond with the heterocyclic N3 atom (Table 1 ▸). The angle between the 4-chloro­phenyl and 1,2,3-triazole planes is 29.8 (1)°.
Figure 1

The mol­ecular structure of the title compound with displacement ellipsoids drawn at the 50% probability level.

Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯A D—HH⋯A DA D—H⋯A
N4—H4⋯N30.862.242.680 (3)112
N4—H4⋯N2i 0.862.683.491 (2)157
C15—H15⋯O10.932.392.936 (2)117
C19—H19⋯N2i 0.932.683.475 (3)144
C2—H2⋯O1ii 0.932.533.439 (3)167
C11—H11⋯O10.982.473.124 (2)124

Symmetry codes: (i) ; (ii) .

Supra­molecular features

As shown in Fig. 2 ▸ and Table 2 ▸, the extended structure of the title compound is consolidated by a number of inter­molecular inter­actions. Two mol­ecules arranged in a near coplanar manner relative to the triazole ring planes are inter­connected by N4—H4⋯N2i and C19—H19⋯N2i hydrogen bonds into a homodimer. Within the dimer, the edge-to-face stacked aromatic rings are tilted by 58.0 (3)°. Atom O1 of the amide group accepts both an intra­molecular C—H⋯O link (with the 4-chloro­phenyl and cyclo­propyl H atoms) and an inter­molecular C2—H2⋯O1 inter­action with the 4-meth­oxy­phenyl H atom. The last of these links neighbouring dimers into hydrogen-bonded ribbons parallel to the [010] direction (Fig. 3 ▸).
Figure 2

The hydrogen bonding of mol­ecules in the title compound. Hydrogen bonds are shown as dashed lines. The symmetry codes are as in Table 1 ▸.

Table 2

Experimental details

Crystal data
Chemical formulaC19H17ClN4O2
M r 368.82
Crystal system, space groupMonoclinic, P21/n
Temperature (K)293
a, b, c (Å)10.5673 (4), 8.0182 (3), 21.2318 (10)
β (°)95.282 (4)
V3)1791.35 (13)
Z 4
Radiation typeMo Kα
μ (mm−1)0.24
Crystal size (mm)0.5 × 0.08 × 0.07
 
Data collection
DiffractometerOxford Diffraction Xcalibur3 CCD
Absorption correctionMulti-scan (CrysAlis RED; Oxford Diffraction, 2005)
T min, T max 0.890, 0.982
No. of measured, independent and observed [I > 2σ(I)] reflections10913, 3475, 1534
R int 0.046
(sin θ/λ)max−1)0.617
 
Refinement
R[F 2 > 2σ(F 2)], wR(F 2), S 0.040, 0.053, 1.05
No. of reflections3475
No. of parameters236
H-atom treatmentH-atom parameters constrained
Δρmax, Δρmin (e Å−3)0.14, −0.19

Computer programs: CrysAlis PRO (Oxford Diffraction, 2005 ▸), SHELXT (Sheldrick, 2015a ▸), SHELXL (Sheldrick, 2015b ▸) and OLEX2 (Dolomanov et al., 2009 ▸).

Figure 3

A view along the a axis of the crystal packing of the title compound.

Hirshfeld surface analysis and computational study

Hirshfeld surface analysis was used to analyse the various inter­molecular inter­actions in the title compound, through mapping the normalized contact distance (d norm) using CrystalExplorer (Turner et al., 2017 ▸; Spackman & Jayatilaka, 2009 ▸). Hirshfeld surfaces enable the visualization of inter­molecular inter­actions by using different colours and colour intensity to represent short or long contacts and indicate the relative strength of the inter­actions. The most prominent inter­actions (the ortho-proton of the aryl­triazole moiety and the carbonyl group as well as bifurcated inter­actions among protons of the amide group and the ortho-proton of the aryl group with the triazole ring nitro­gen (N2) atoms of neighbouring mol­ecules) can be seen in the Hirshfeld surface plot as red areas (Fig. 4 ▸). Fingerprint plots were produced to show the inter­molecular surface bond distances with the regions highlighted for (C)H⋯O and (C, N)H⋯N inter­actions (Fig. 4 ▸). The contribution to the surface area for such contacts are 11.6% and 10.8%, respectively.
Figure 4

(a) Hirshfeld surface for the title mol­ecule mapped with d norm over the range −0.171 to 1.473 a.u. showing N—H⋯N, C—H⋯N and C—H⋯O hydrogen-bonded contacts. Fingerprint plots resolved into (b) N⋯H/H⋯N and (c) O⋯H/H⋯O contacts. Neighbouring mol­ecules associated with close contacts are also shown.

The frontier mol­ecular orbitals HOMO and LUMO were analysed to better understand the electronic charge transfer within the mol­ecule and its electron donating and accepting ability. The mol­ecular orbital energies were calculated using the B3LYP functional level with the 6-31+G* basis set in a vacuum with GAMESS software (Schmidt et al., 1993 ▸). The HOMO and LUMO orbitals were found to be well separated in energy and largely localized on the 4-chloro­phenyl amide or aryl­triazole motifs, respectively (Fig. 5 ▸). Their respective energy values were estimated to be −5.9 eV and −0.8 eV.
Figure 5

Frontier mol­ecular orbital energies.

Database survey

The closest related compounds containing a similar 1-aryl-1H-1,2,3-triazole-4-carboxamide skeleton to the title compound but with different substituents on the amide are: (S)-1-(4-chloro­phen­yl)-N-(−1-hy­droxy-3-phenyl­propan-2-yl)-5-meth­yl-1H-1,2,3-triazole-4-carboxamide (I) (CCDC refcode: ZIPSEY; Shen et al., 2013 ▸), 1-(4-chloro­phen­yl)-5-methyl-N-[(3-phenyl-1,2-oxazol-5-yl)meth­yl]-1H-1,2,3-triazole-4-carb­ox­amide (II) (LELHOB; Niu et al., 2013 ▸), (5-methyl-1-(8-[tri­fluoro­meth­yl)quinolin-4-yl]-1H-1,2,3-triazol-4-yl)morph­o­lino)­methanone (III) (LOHWIP; Anuradha et al., 2008 ▸) and 1-(3-amino-5-(3-hy­droxy-3-methyl­but-1-yn-1-yl)phen­yl)-N-butyl-1H-1,2,3-triazole-4-carboxamide (IV) (BEBJEZ; Li et al., 2012 ▸). Compounds (I) and (II) crystallize in the monoclinic crystal system [non-centrosymmetric space group P21 in (I) and centrosymmetric P21/c in (II)], while compounds (III) and (IV) crystallize in the triclinic space group P . Structure (I) contains two crystallographically independent mol­ecules, the hydroxyl groups of which participate in inter­molecular O—H⋯O hydrogen bonds. In contrast to the structure of title compound, the dihedral angles between the phenyl rings and triazole rings in (I) are −45.2 (6)° (C5—C6—N1—N2) and 39.9 (6)° (C1′—C6′—N1′—N2′). The analogous angle in (II) is 19.2 (2)°. In structure (II), the carboxamide groups connect neighbouring mol­ecules into infinite hydrogen-bonded chains by means of N—H⋯O hydrogen bonds: these are linked by N—H⋯O (oxazole) contacts into a three-dimensional framework. Similarly to (I) and (II), structure (III) contains a 5-methyl substituent at the triazole ring and, because of significant steric hindrance of the 8-(tri­fluoro­meth­yl)quinoline group, the dihedral angle between the rings is 54.7°. The phenyl and triazole rings in (IV) are close to coplanar (7.5°), while the hydroxyl, carboxamide and amino groups participate in O—H⋯O and N—H⋯O hydrogen bonds. Finally, two copper(I) π-complexes with compositions [Cu(C12H13N5O)(NO3)0.5H2O and [Cu(C12H13N5O)(CF3COO)] (C12H13N5O is N-allyl-5-amino-1-phenyl-1H-1,2,3-triazole-4-carboxamide) were obtained by electrochemical synthesis (ZEQTOG and ZEQTUM; Slyvka et al., 2012 ▸). Crystals of both compounds are monoclinic, space group C2/c. In both structures, the N-allyl-1H-1,2,3-triazole-4-carboxamide moiety acts as a bridging chelating ligand and forms, with the copper(I) atoms, infinite chains containing [CuC4NO] seven-membered rings.

Synthesis and crystallization

The title compound was synthesized from 5-cyclo­propyl-1-(4-meth­oxy­phen­yl)-1H-1,2,3-triazole-4-carb­oxy­lic acid (Pokhodylo et al., 2017 ▸) by the following procedure (Fig. 6 ▸). 5-Cyclo­propyl-1-(4-meth­oxy­phen­yl)-1H-1,2,3-triazole-4-carb­oxy­lic acid 1 (1.3 g, 5.0 mmol) was added to a solution of 1,1′-carbonyl­diimidazole (0.81 g, 5.0 mmol) in dry aceto­nitrile (25 ml) and the mixture was kept for 30 min at 323 K. Then 4-chloro­aniline 2 (0.64 g, 5.0 mmol) was added, and the mixture was heated at 343 K for 1 h. After cooling to room temperature, water (30 ml) was added. The precipitate was filtered off, washed with water on a filter, recrystallized from ethanol solution, and dried in air to give the title compound as colourless prismatic crystals, m.p. 422–423 K; 1H NMR (500 MHz, DMSO-d 6) δ 10.56 (s, 1H, NH), 7.89 (d, J = 8.6 Hz, 2H, HAr), 7.58 (d, J = 8.6 Hz, 2H, HAr), 7.39 (d, J = 8.6 Hz, 2H, HAr), 7.16 (d, J = 8.6 Hz, 2H, HAr), 3.86 (s, 3H, MeO), 2.10–1.99 (m, 1H, cPrCH), 0.95–0.80 (m, 4H, cPrCH2); 13C NMR (126 MHz, DMSO-d 6) δ 160.62 (C=O or CAr—O), 159.60 (C=O or CAr—O), 142.26 (CTriazole-4), 138.87 (CTriazole-5), 138.21 (CClAr-1), 129.08 (CAr-1), 128.91 (2 × CClAr-3,5), 127.77 (2 × CAr-2,6), 127.70 (CClAr-4), 122.25 (2 × CClAr-2,6), 115.00 (2 × CAr-3,5), 56.06 (MeO), 8.09 (2 × CH2 cPr), 5.75 (CHcPr); MS m/z = 369 (M ++1); Analysis calculated for C19H17ClN4O2 (M r = 368.82), (%): C 61.88, H 4.65, N 15.19; found (%): C 61.91, H 4.74, N 15.21.
Figure 6

Synthesis of N-(4-chloro­phen­yl)-5-cyclo­propyl-1-(4-meth­oxy­phen­yl)-1H-1,2,3-triazole-4-carboxamide.

Refinement

Crystal data, data collection and structure refinement details are summarized in Table 2 ▸. All H atoms were positioned geometrically with N—H = 0.86 Å and C—H = 0.93–0.98 Å and refined as riding atoms. The constraint U iso(H) = 1.2U eq(carrier) or 1.5U eq(C-methyl carrier) was applied in all cases. Crystal structure: contains datablock(s) global, I. DOI: 10.1107/S2056989020005848/hb7901sup1.cif Structure factors: contains datablock(s) I. DOI: 10.1107/S2056989020005848/hb7901Isup2.hkl Click here for additional data file. Supporting information file. DOI: 10.1107/S2056989020005848/hb7901Isup3.mol Click here for additional data file. Supporting information file. DOI: 10.1107/S2056989020005848/hb7901Isup4.cml CCDC reference: 1999643 Additional supporting information: crystallographic information; 3D view; checkCIF report
C19H17ClN4O2F(000) = 768
Mr = 368.82Dx = 1.368 Mg m3
Monoclinic, P21/nMo Kα radiation, λ = 0.71073 Å
a = 10.5673 (4) ÅCell parameters from 1540 reflections
b = 8.0182 (3) Åθ = 0.9–1.0°
c = 21.2318 (10) ŵ = 0.24 mm1
β = 95.282 (4)°T = 293 K
V = 1791.35 (13) Å3Prism, colourless
Z = 40.5 × 0.08 × 0.07 mm
Oxford Diffraction Xcalibur3 CCD diffractometer1534 reflections with I > 2σ(I)
ω scansRint = 0.046
Absorption correction: multi-scan (CrysAlis RED; Oxford Diffraction, 2005)θmax = 26.0°, θmin = 2.7°
Tmin = 0.890, Tmax = 0.982h = −12→12
10913 measured reflectionsk = −5→9
3475 independent reflectionsl = −25→26
Refinement on F20 restraints
Least-squares matrix: fullHydrogen site location: inferred from neighbouring sites
R[F2 > 2σ(F2)] = 0.040H-atom parameters constrained
wR(F2) = 0.053w = 1/[σ2(Fo2) + (0.0071P)2 + 0.050P] where P = (Fo2 + 2Fc2)/3
S = 1.05(Δ/σ)max = 0.001
3475 reflectionsΔρmax = 0.14 e Å3
236 parametersΔρmin = −0.19 e Å3
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
xyzUiso*/Ueq
Cl11.19945 (6)0.04278 (8)0.35044 (3)0.0860 (2)
O10.80102 (13)0.41861 (18)0.54511 (7)0.0627 (5)
O20.01792 (15)0.44313 (19)0.73741 (7)0.0686 (5)
N40.75389 (15)0.1763 (2)0.49150 (8)0.0524 (5)
H40.6958190.1013740.4852720.063*
N10.43143 (16)0.3069 (2)0.60195 (9)0.0556 (5)
C140.8626 (2)0.1540 (2)0.45845 (11)0.0443 (6)
C10.3243 (2)0.3477 (2)0.63661 (12)0.0492 (6)
C90.5403 (2)0.3903 (2)0.59331 (10)0.0479 (6)
C40.1154 (2)0.4142 (3)0.70082 (12)0.0512 (6)
C100.7294 (2)0.3016 (3)0.53206 (11)0.0505 (6)
N30.53626 (18)0.1428 (2)0.54590 (10)0.0763 (7)
C150.9796 (2)0.2218 (2)0.47738 (10)0.0520 (6)
H150.9891970.2904450.5128040.062*
C80.6050 (2)0.2842 (3)0.55768 (11)0.0486 (6)
C30.11310 (19)0.4532 (2)0.63777 (11)0.0546 (6)
H30.0411470.5015190.6167700.066*
N20.43009 (18)0.1551 (2)0.57229 (11)0.0831 (7)
C190.84942 (19)0.0551 (3)0.40452 (10)0.0539 (6)
H190.7702960.0110770.3906620.065*
C20.2188 (2)0.4199 (3)0.60555 (10)0.0546 (6)
H20.2180480.4466670.5628900.066*
C161.0831 (2)0.1881 (3)0.44386 (11)0.0573 (7)
H161.1621980.2333510.4569010.069*
C110.57821 (19)0.5584 (3)0.61661 (11)0.0596 (6)
H110.6580790.5969100.6014920.072*
C180.9525 (2)0.0218 (2)0.37150 (10)0.0585 (7)
H180.943421−0.0454180.3356860.070*
C171.0685 (2)0.0881 (3)0.39158 (11)0.0533 (6)
C50.2213 (2)0.3398 (3)0.73129 (11)0.0635 (7)
H50.2221480.3122570.7738730.076*
C60.3263 (2)0.3056 (3)0.69943 (12)0.0623 (7)
H60.3974300.2546420.7201600.075*
C130.5580 (2)0.6216 (3)0.68014 (12)0.0782 (8)
H13A0.5118490.5509920.7072040.094*
H13B0.6255520.6870840.7021180.094*
C120.4869 (2)0.6965 (3)0.62524 (13)0.0809 (8)
H12A0.5106720.8080590.6130840.097*
H12B0.3968820.6718630.6181740.097*
C7−0.0993 (2)0.4984 (3)0.70643 (12)0.0970 (9)
H7A−0.1283820.4196580.6742410.146*
H7B−0.0876130.6053040.6874330.146*
H7C−0.1611440.5076740.7366410.146*
U11U22U33U12U13U23
Cl10.0723 (5)0.0988 (5)0.0925 (5)0.0004 (4)0.0379 (4)−0.0087 (4)
O10.0573 (10)0.0568 (10)0.0765 (12)−0.0187 (8)0.0189 (9)−0.0171 (9)
O20.0585 (11)0.0879 (12)0.0627 (12)0.0026 (9)0.0231 (10)0.0082 (9)
N40.0475 (12)0.0478 (12)0.0639 (14)−0.0110 (9)0.0167 (11)−0.0108 (10)
N10.0512 (13)0.0499 (12)0.0682 (15)−0.0072 (11)0.0186 (12)−0.0094 (11)
C140.0454 (15)0.0413 (14)0.0468 (15)−0.0044 (11)0.0087 (14)−0.0008 (12)
C10.0468 (16)0.0458 (14)0.0565 (18)−0.0048 (12)0.0130 (15)−0.0036 (13)
C90.0480 (15)0.0428 (14)0.0534 (16)−0.0059 (12)0.0067 (14)−0.0038 (12)
C40.0516 (17)0.0527 (15)0.0507 (17)−0.0039 (12)0.0127 (15)0.0017 (13)
C100.0562 (17)0.0463 (15)0.0501 (16)0.0002 (13)0.0103 (15)−0.0024 (13)
N30.0591 (14)0.0633 (15)0.1115 (19)−0.0171 (11)0.0347 (14)−0.0363 (12)
C150.0512 (15)0.0488 (15)0.0553 (18)−0.0033 (12)0.0013 (15)−0.0112 (12)
C80.0436 (15)0.0443 (15)0.0589 (17)−0.0099 (12)0.0110 (14)−0.0123 (12)
C30.0493 (15)0.0617 (15)0.0540 (17)0.0043 (12)0.0109 (14)0.0055 (13)
N20.0665 (16)0.0618 (14)0.127 (2)−0.0215 (11)0.0420 (15)−0.0392 (13)
C190.0503 (15)0.0561 (14)0.0564 (16)−0.0130 (12)0.0109 (14)−0.0093 (13)
C20.0619 (17)0.0589 (15)0.0434 (15)−0.0041 (14)0.0065 (15)0.0055 (12)
C160.0456 (16)0.0629 (16)0.0644 (19)−0.0073 (13)0.0105 (15)−0.0063 (14)
C110.0580 (16)0.0533 (15)0.0704 (18)−0.0040 (13)0.0210 (14)−0.0185 (14)
C180.0657 (17)0.0595 (16)0.0520 (16)−0.0095 (14)0.0143 (15)−0.0114 (12)
C170.0523 (16)0.0561 (15)0.0542 (17)0.0004 (13)0.0198 (14)0.0034 (13)
C50.0602 (18)0.0838 (18)0.0474 (17)−0.0001 (14)0.0095 (16)0.0168 (14)
C60.0478 (17)0.0717 (17)0.067 (2)0.0024 (13)0.0025 (16)0.0143 (15)
C130.083 (2)0.0669 (18)0.085 (2)−0.0152 (15)0.0110 (19)−0.0197 (16)
C120.073 (2)0.0489 (16)0.119 (2)0.0045 (14)−0.0003 (19)−0.0099 (17)
C70.0580 (18)0.136 (3)0.102 (2)0.0258 (17)0.0314 (17)0.0219 (19)
Cl1—C171.742 (2)C3—H30.9300
O1—C101.221 (2)C3—C21.389 (3)
O2—C41.366 (2)C19—H190.9300
O2—C71.419 (2)C19—C181.375 (3)
N4—H40.8600C2—H20.9300
N4—C141.412 (2)C16—H160.9300
N4—C101.364 (2)C16—C171.367 (3)
N1—C11.443 (2)C11—H110.9800
N1—C91.358 (2)C11—C131.475 (3)
N1—N21.370 (2)C11—C121.491 (3)
C14—C151.376 (3)C18—H180.9300
C14—C191.389 (2)C18—C171.367 (3)
C1—C21.370 (3)C5—H50.9300
C1—C61.374 (3)C5—C61.379 (3)
C9—C81.363 (2)C6—H60.9300
C9—C111.478 (3)C13—H13A0.9700
C4—C31.373 (3)C13—H13B0.9700
C4—C51.376 (3)C13—C121.457 (3)
C10—C81.476 (3)C12—H12A0.9700
N3—C81.357 (2)C12—H12B0.9700
N3—N21.303 (2)C7—H7A0.9600
C15—H150.9300C7—H7B0.9600
C15—C161.385 (3)C7—H7C0.9600
C4—O2—C7117.47 (18)C15—C16—H16120.1
C14—N4—H4115.9C17—C16—C15119.8 (2)
C10—N4—H4115.9C17—C16—H16120.1
C10—N4—C14128.10 (18)C9—C11—H11113.1
C9—N1—C1132.18 (19)C9—C11—C12124.1 (2)
C9—N1—N2110.40 (17)C13—C11—C9124.2 (2)
N2—N1—C1117.40 (17)C13—C11—H11113.1
C15—C14—N4123.7 (2)C13—C11—C1258.84 (14)
C15—C14—C19119.1 (2)C12—C11—H11113.1
C19—C14—N4117.2 (2)C19—C18—H18120.2
C2—C1—N1119.5 (2)C17—C18—C19119.7 (2)
C2—C1—C6120.7 (2)C17—C18—H18120.2
C6—C1—N1119.8 (2)C16—C17—Cl1119.63 (19)
N1—C9—C8103.98 (17)C16—C17—C18120.8 (2)
N1—C9—C11127.6 (2)C18—C17—Cl1119.56 (18)
C8—C9—C11128.4 (2)C4—C5—H5119.6
O2—C4—C3124.7 (2)C4—C5—C6120.8 (2)
O2—C4—C5115.5 (2)C6—C5—H5119.6
C3—C4—C5119.9 (2)C1—C6—C5119.1 (2)
O1—C10—N4124.08 (19)C1—C6—H6120.5
O1—C10—C8122.9 (2)C5—C6—H6120.5
N4—C10—C8113.0 (2)C11—C13—H13A117.7
N2—N3—C8108.94 (17)C11—C13—H13B117.7
C14—C15—H15119.9H13A—C13—H13B114.8
C14—C15—C16120.2 (2)C12—C13—C1161.14 (16)
C16—C15—H15119.9C12—C13—H13A117.7
C9—C8—C10130.9 (2)C12—C13—H13B117.7
N3—C8—C9109.70 (18)C11—C12—H12A117.8
N3—C8—C10119.4 (2)C11—C12—H12B117.8
C4—C3—H3120.2C13—C12—C1160.02 (15)
C4—C3—C2119.6 (2)C13—C12—H12A117.8
C2—C3—H3120.2C13—C12—H12B117.8
N3—N2—N1106.97 (17)H12A—C12—H12B114.9
C14—C19—H19119.8O2—C7—H7A109.5
C18—C19—C14120.4 (2)O2—C7—H7B109.5
C18—C19—H19119.8O2—C7—H7C109.5
C1—C2—C3120.0 (2)H7A—C7—H7B109.5
C1—C2—H2120.0H7A—C7—H7C109.5
C3—C2—H2120.0H7B—C7—H7C109.5
O1—C10—C8—C96.7 (4)C4—C5—C6—C10.4 (3)
O1—C10—C8—N3−173.6 (2)C10—N4—C14—C1523.3 (4)
O2—C4—C3—C2179.10 (19)C10—N4—C14—C19−158.0 (2)
O2—C4—C5—C6−179.5 (2)C15—C14—C19—C181.7 (3)
N4—C14—C15—C16177.1 (2)C15—C16—C17—Cl1−178.77 (17)
N4—C14—C19—C18−177.10 (19)C15—C16—C17—C180.6 (3)
N4—C10—C8—C9−171.8 (2)C8—C9—C11—C13−139.8 (3)
N4—C10—C8—N37.9 (3)C8—C9—C11—C12147.4 (3)
N1—C1—C2—C3177.23 (19)C8—N3—N2—N1−0.5 (3)
N1—C1—C6—C5−177.6 (2)C3—C4—C5—C60.8 (3)
N1—C9—C8—C10179.6 (2)N2—N1—C1—C2−86.6 (2)
N1—C9—C8—N3−0.1 (3)N2—N1—C1—C689.8 (3)
N1—C9—C11—C1341.2 (4)N2—N1—C9—C8−0.2 (2)
N1—C9—C11—C12−31.6 (4)N2—N1—C9—C11179.1 (2)
C14—N4—C10—O11.2 (4)N2—N3—C8—C90.4 (3)
C14—N4—C10—C8179.7 (2)N2—N3—C8—C10−179.4 (2)
C14—C15—C16—C170.5 (3)C19—C14—C15—C16−1.6 (3)
C14—C19—C18—C17−0.7 (3)C19—C18—C17—Cl1178.88 (17)
C1—N1—C9—C8178.1 (2)C19—C18—C17—C16−0.5 (3)
C1—N1—C9—C11−2.7 (4)C2—C1—C6—C5−1.2 (3)
C1—N1—N2—N3−178.2 (2)C11—C9—C8—C100.4 (4)
C9—N1—C1—C295.2 (3)C11—C9—C8—N3−179.3 (2)
C9—N1—C1—C6−88.4 (3)C5—C4—C3—C2−1.2 (3)
C9—N1—N2—N30.4 (3)C6—C1—C2—C30.8 (3)
C9—C11—C13—C12−112.4 (3)C7—O2—C4—C38.1 (3)
C9—C11—C12—C13112.6 (3)C7—O2—C4—C5−171.63 (19)
C4—C3—C2—C10.4 (3)
D—H···AD—HH···AD···AD—H···A
N4—H4···N30.862.242.680 (3)112
N4—H4···N2i0.862.683.491 (2)157
C15—H15···O10.932.392.936 (2)117
C19—H19···N2i0.932.683.475 (3)144
C2—H2···O1ii0.932.533.439 (3)167
C11—H11···O10.982.473.124 (2)124
  13 in total

1.  Amidetriazole: a versatile building block for construction of oxyanion anion receptors.

Authors:  Yong-Jun Li; Liang Xu; Wen-Long Yang; Hui-Biao Liu; Siu-Wai Lai; Chi-Ming Che; Yu-Liang Li
Journal:  Chemistry       Date:  2012-02-29       Impact factor: 5.236

2.  Chemoselective preparation of 1,2,3-triazole-isoxazole bisfunctional derivatives and their application in peptidomimetic synthesis.

Authors:  Teng-fei Niu; Mei-fang Lv; Liang wang; Wen-bin Yi; Chun Cai
Journal:  Org Biomol Chem       Date:  2013-01-07       Impact factor: 3.876

3.  Discovery andw biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors.

Authors:  Shunguang Zhou; Huimin Liao; Mingmei Liu; Guobing Feng; Baolin Fu; Ruijuan Li; Maosheng Cheng; Yanfang Zhao; Ping Gong
Journal:  Bioorg Med Chem       Date:  2014-09-28       Impact factor: 3.641

4.  Rufinamide: a novel broad-spectrum antiepileptic drug.

Authors:  James W Wheless; Blanca Vazquez
Journal:  Epilepsy Curr       Date:  2010-01       Impact factor: 7.500

5.  Antivirally active ribavirin analogues--4,5-disubstituted 1,2,3-triazole nucleosides: biological evaluation against certain respiratory viruses and computational modelling.

Authors:  Anna Krajczyk; Katarzyna Kulinska; Tadeusz Kulinski; Brett L Hurst; Craig W Day; Donald F Smee; Tomasz Ostrowski; Piotr Januszczyk; Joanna Zeidler
Journal:  Antivir Chem Chemother       Date:  2014-01-29

6.  Synthesis and in vitro evaluation of potential anticancer activity of mono- and bis-1,2,3-triazole derivatives of bis-alkynes.

Authors:  Hichem Elamari; Riadh Slimi; Guy G Chabot; Lionel Quentin; Daniel Scherman; Christian Girard
Journal:  Eur J Med Chem       Date:  2012-12-20       Impact factor: 6.514

7.  {5-Methyl-1-[8-(trifluoro-meth-yl)quinolin-4-yl]-1H-1,2,3-triazol-4-yl}(morpholino)methanone.

Authors:  N Anuradha; A Thiruvalluvar; M Mahalinga; R J Butcher
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-11-20

8.  SHELXT - integrated space-group and crystal-structure determination.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A Found Adv       Date:  2015-01-01       Impact factor: 2.290

9.  Crystal structure refinement with SHELXL.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr C Struct Chem       Date:  2015-01-01       Impact factor: 1.172

10.  Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-BclxL strategies through Mcl-1 down-regulation.

Authors:  Marie-Laure Bonnefond; Romane Florent; Sophie Lenoir; Bernard Lambert; Edwige Abeilard; Florence Giffard; Marie-Hélène Louis; Nicolas Elie; Mélanie Briand; Denis Vivien; Laurent Poulain; Pascal Gauduchon; Monique N'Diaye
Journal:  Oncotarget       Date:  2018-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.